Párraga-Martínez Ignacio, Escobar-Rabadán Francisco, Rabanales-Sotos Joseba, Lago-Deibe Fernando, Téllez-Lapeira Juan M, Villena-Ferrer Alejandro, Blasco-Valle Mariano, Ferreras-Amez José M, Morena-Rayo Susana, Del Campo-Del Campo José M, Ayuso-Raya M Candelaria, Pérez-Pascual José J
Centro de Salud de La Roda, Gerencia de Atención Integrada de Albacete, Servicio de Salud de Castilla-La Mancha, Facultad de Medicina de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain.
Centro de Salud Zona IV, Servicio de Salud de Castilla-La Mancha, Albacete, Spain.
Rev Esp Cardiol (Engl Ed). 2018 Jan;71(1):33-41. doi: 10.1016/j.rec.2017.05.029. Epub 2017 Jun 23.
Several interventions can improve low-density lipoprotein cholesterol (LDL-C) control. Our main objective was to evaluate the efficacy of a combined intervention to improve LDL-C control in patients with hypercholesterolemia. The study also assessed the efficacy of the intervention in improving adherence (pharmacological, diet, and exercise).
A multicenter, parallel group, randomized clinical trial (primary care) was conducted in 358 adults diagnosed with hypercholesterolemia, whether receiving prior drug therapy or not. We compared 178 participants who received the combined intervention (written material, self-completed registration cards, and messages to mobile telephones) with 178 controls. The main outcome variable was the proportion of participants with adequate LDL-C control (target levels of the European guidelines on dyslipidemia and cardiovascular risk) at 24 months.
At 24 months, the mean reduction in LDL-C was significantly higher in the intervention group (23.8mg/dL [95%CI, 17.5-30.1]) than in the control group (14.6mg/dL [95%CI, 8.9-20.4]; P=.034). The mean LDL-C decrease was 13.1%±28.6%. At 1 year, the proportion of participants with adequate control was significantly higher in the intervention group than in the control group (43.7% vs 30.1%; P=.011; RR, 1.46). Adherence was significantly higher in the intervention group, both to drug therapy (77.2% vs 64.1%; P=.029) and exercise (64.9% vs 35.8; P<.001), but not to diet.
The combined intervention significantly reduced LDL-C (by more than 13% at 2 years) and improved the degree of LDL-C control in patients with hypercholesterolemia at 1 year.
多种干预措施可改善低密度脂蛋白胆固醇(LDL-C)的控制情况。我们的主要目的是评估一种联合干预措施对改善高胆固醇血症患者LDL-C控制情况的疗效。该研究还评估了该干预措施在提高依从性(药物治疗、饮食和运动方面)的疗效。
在358名诊断为高胆固醇血症的成年人中开展了一项多中心、平行组、随机临床试验(初级保健),这些患者无论之前是否接受过药物治疗。我们将178名接受联合干预(书面材料、自行填写的登记卡以及手机短信)的参与者与178名对照组进行了比较。主要结局变量是在24个月时LDL-C得到充分控制(血脂异常和心血管风险欧洲指南的目标水平)的参与者比例。
在24个月时,干预组LDL-C的平均降低幅度(23.8mg/dL [95%CI,17.5 - 30.1])显著高于对照组(14.6mg/dL [95%CI,8.9 - 20.4];P = 0.034)。LDL-C的平均降低幅度为13.1%±28.6%。在1年时,干预组中控制良好的参与者比例显著高于对照组(43.7%对30.1%;P = 0.011;RR,1.46)。干预组在药物治疗(77.2%对64.1%;P = 0.029)和运动(64.9%对35.8;P < 0.001)方面的依从性显著更高,但在饮食方面并非如此。
联合干预显著降低了LDL-C(2年时降低超过13%),并在1年时改善了高胆固醇血症患者LDL-C的控制程度。